

# Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection

NCT04308278

---

Status	RECRUITING
Phase	Phase 4
Sponsor	LaboLife
Enrollment	88 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Patients, male or female, aged 12 years and older,
- Patient with fatigue for 1 month or more,
- Patient with at least two other symptoms among the following: Long-lasting exhaustion even after light exertion, subfebrile state, fever, loss of appetite, nausea, angina, conjunctivis, sensitive cervical or axillary lymph nodes, erythematous and swollen tonsil, headaches, sore throat, myalgia, muscular weakness, arthralgia, splenomegaly, visual disorders, memory disorders, attention deficit disorders, sleep disorders, gastrointestinal disorders, breathing disorders, cardiovascular disorders.
- Patient (and/or parents if necessary) agrees to perform serology for the study,
- Patient (and/or parents if necessary) agrees to perform lymphocyte typing for the study during the pre-inclusion visit,
- ... and 3 more (see full listing online)

### Exclusion (13)

- Patient who have received any treatment with the 2LEBV® or 2LXFS®,
- Patients who have received any homeopathic treatment in the previous 2 months prior to the study,
- Patients under immunosuppressive treatment,
- Patient undergoing treatment for psychiatric disorders,
- Patients having received immunotherapy or micro-immunotherapy during the last 3 months,
- ... and 8 more (see full listing online)

## Locations (12 total)

---

Private Practice, Aartselaar, Belgium  
Private Practice, Boortmeerbeek, Belgium  
Private Practice, Brussels, Belgium  
... and 9 more locations